Coronavirus / COVID

The company dosed its first study participant with its investigational vaccine, mRNA-1083. And this follows recent data reported from their phase 1/2 trial where the vaccine showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile.

The federal agency sent out a health advisory to change the prescribing recommendations for the newer preventative respiratory syncytial virus (RSV) monoclonal antibody.

If approved, it would become the first nasal flu vaccine to be self-administered.

Association with Epstein-Barr virus reactivation sets the need for an antiviral clinical trial with cardiopulmonary exercise testing as an endpoint.

The company plans to begin a phase 3 trial for its mRNA-1083 investigational combination vaccine later this year.

The updated emergency user authorization follows similar approvals and authorizations for Moderna and Pfizer's COVID-19 vaccines.

Small study shows infected macrophages and foam cells cause cytokines to be released and may help explain why patients have cardiovascular complications long after getting the infection.

The findings show that treatment with the COVID-19 oral antiviral can develop into different strains and spread.

These novel vaccines are utilizing a self-amplifying messenger RNA (sa-mRNA) vaccine platform. Study data was reported at the ESWI Influenza Conference in Spain.

The federal agency’s Advisory Committee on Immunization Practices (ACIP) recommendation was to authorize and approve the updated 2023-2024 (monovalent, XBB containing) COVID-19 vaccines for persons 6 months of age and older.

Misinformation created unnecessary hospitalizations and mortality and demonstrated the chasm in public health communication.

The agency specified which age groups the vaccine is approved for and which are authorized to use them, paving the way for fall vaccinations to take place.

The company says its vaccine protects against the BA286 strain.

The European Medicines Agency (EMA) based its decision on preclinical data showing that the Omicron XBB.1.5-adapted monovalent COVID-19 vaccine generates an improved response against multiple XBB-related sublineages, including XBB15, XBB116, XBB23, and EG51.

The CDC reports the original COVID-19 monovalent and bivalent vaccines helped reduce emergency department or urgent care encounters for children aged 6 months to 5 years.

Clinicians offer insights on the individual respiratory viruses as well as addressing management of coinfections.

Masking to reduce COVID-19 transmission risk is required at a few colleges and one major movie studio.

Viruses and other concerns within medicine are being overlooked; health care preparedness must address these potential crises.

Social media platforms, public health agencies, and communities must join forces to stop the rapid spread of false information.

The strain, Eris (EG5), is from the Omicron lineage, and the expectations are the newest vaccines will protect against it, and other variants from the same family.

Surveillance data such as hospitalizations and wastewater metrics provide real COVID-19 prevalence numbers, but do we need to do more to be prepared ahead of another potential health crisis?

A new study confirms this form of surveillance to collect metrics for SARS-CoV-2 to understand infection prevalence on a bigger scale.

A new study demonstrated Moderna having a greater efficacy and slightly less adverse event profile in this patient population vs the Pfizer-BioNTech vaccine.

New report published this week shows the decrease over the last 2 reportable years.

Patients with cancer, cancer survivors, and matched controls maintained immunity against severe COVID-19 for at least 5 months after a third or fourth vaccine dose.